Great place to DD stocks:

DraftKings' Surprising Turn of Fortune Talk about a gut punch! DraftKings (NASDAQ: DKNG) dropped a bombshell that had investors reeling. They decided to lop off a hefty slice of their revenue guidance, and trust me, those aren't small numbers we’re talking about. On November 6, they yanked their full-year 2026 revenue guidance down to $6.35 billion to $6.55 billion from...

A Legal Eagle Soars High in 2027 Oh, the legal world can be as cutthroat as the stock market some days, especially when you're gunning for those top-tier rankings. This year, McKinley Irvin has managed to ruffle a few feathers in the Pacific Northwest, claiming top honors in the 2027 Best Law Firms rankings. And let me tell you, this wasn’t just handed to them on a...

Legal waters are as choppy as the seas themselves, especially in the maritime injury law arena. Nicholas J. Neidzwski, a maritime injury attorney and partner at BoatLaw, LLP, recently waded into these turbulent waters at the 2026 Pacific Admiralty Seminar. This isn’t just any gathering; it’s the West Coast’s legal beacon on all things maritime, drawing in industry...

Axon's Revenue Forecast Takes a Hit Listen up, folks. Axon Enterprise, Inc. (NASDAQ: AXON) has stirred the pot, cutting their 2026 revenue forecast faster than you can say "counter-drone deployment." Back in August, they were riding high on their second-quarter call, raising their growth forecast to a cheerful 32%-34%. Fast forward to November, and it's been slashed to...

What Tenax Investors Need to Know Alright, folks, time to pull up a chair and pay attention to what's brewing with Tenax Therapeutics—yeah, we're talking NASDAQ: TENX. The company's head is spinning as it's caught up in a securities class action lawsuit. What's the fuss? The fine print here accuses Tenax of misleading investors about the effectiveness of their product,...

The Digital Fiasco: A Wake-Up Call Straight out of Sussex County in good ol' New Jersey, we’re staring down another data breach, folks. When you hear about a data privacy incident, there's always that same sinking feeling of another layer of personal security peeled away. This time, the Sussex County Prosecutor's Office got caught in the crossfire, with personal info...

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Analyzing Mynd.ai's ADS Ratio Tweak When Mynd.ai decides to shake things up with the American Depositary Shares (ADS) ratio, it's like they're throwing a curveball straight at Wall Street. Listen up, this isn't just a deck shuffle—it's a fundamental tweak that could play a big role in the stock’s perceived value. Starting December 7, 2027, one ADS will leap from...

Diving Deep into Supply Chain Disturbances Accrete's making waves in the supply chain game with a fresh move that's got the sector talking. Partnering with TenderAlpha, they're pulling strings to provide federal agencies with deeper supply chain insights. You see, Accrete, the brainy bunch driving Knowledge Engines, is sharpening its focus on those unseen tangles in the...

Muyuan Foods Ready to Impress at EuroTier 2026 Let's face it, folks—when you think of game-changers in pig farming, Muyuan Foods Group deserves a nod. They're not just trotting out oinkers left and right; they're steering the whole paddock with innovations in smart pig farming and green development solutions. At EuroTier 2026 in Hanover, Muyuan’s booth—J04 in Hall...

ImmunityBio's Journey Towards EU Approval The European Medicines Agency (EMA) has made a significant recommendation toward approving ImmunityBio, Inc.’s Anktiva (nogapendekin alfa inbakicept), intended for use alongside Bacillus Calmette-Guérin (BCG) for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Clinical Trial Results and Findings This...

Temperature Monitoring Systems Market Analysis and Growth Projections The temperature monitoring systems market, valued at USD 3.80 billion recently, is on a promising trajectory. It is expected to expand at a compound annual growth rate (CAGR) of 5.3%, reaching an impressive USD 5.66 billion by 2030. This growth can be attributed to several factors, including...

Performance Insights into Apple and Industry Competitors In the ever-evolving realm of technology, understanding the dynamics of company performance is vital for investors and analysts. This analysis focuses on Apple Inc. (NASDAQ: AAPL) and its key competitors in the Technology Hardware, Storage & Peripherals sector. We'll delve into essential financial metrics, market...

X Financial Reveals Strong Q2 Performance X Financial (NYSE: XYF), a prominent player in the fintech industry, has reported robust financial results that highlight its significant growth and commitment to enhancing its service offering. The company recently disclosed its unaudited financial results for the second quarter, and the figures are quite remarkable. Q2 2025...

Tyra Biosciences to Engage Investors at Major Conferences Tyra Biosciences, Inc. (Nasdaq: TYRA) is a pioneering biotechnology company dedicated to crafting next-generation precision medicines with a keen focus on Fibroblast Growth Factor Receptor (FGFR) biology. The company has great momentum as it takes strides in engaging with investors at a series of crucial investor...